 VANCOUVER, British Columbia, March 03, 2021 GLOBE NEWSWIRE -- InMed Pharmaceuticals Inc. InMed or the Company Nasdaq: INM; TSX:IN, a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need and leading the clinical development of cannabinol CBN, today announced that Eric A. Adams, President and CEO of InMed, will be presenting at investor conferences in March 2021. The details of each conference are included below. 